Evidence map›Paper›PMID 39988827›Full record

ArticleAging cell2025

Circular RNA Telomerase Reverses Endothelial Senescence in Progeria.

Weifeng Qin, Kathrina D Castillo, Hongye Li, Thi Kim Cuc Nguyen, Daniel L Kiss, John P Cooke, Anahita Mojiri

Abstract read
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Angiogenesis in Lung Regeneration and Aging.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  3. Multicellular senescence programs in the aged heart.Journal of molecular and cellular cardiology plus · 2026
    Review
  4. Review
  5. Telomerase mRNA therapy protects human skin against radiation-induced DNA damage.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weifeng QinDepartment of Cardiovascular sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0009-0005-3086-6950
Kathrina D CastilloDepartment of Cardiovascular Sciences, Center for RNA Therapeutics, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0003-2764-8491
Hongye LiDepartment of Cardiovascular Sciences, Center for RNA Therapeutics, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0009-0000-5176-8827
Thi Kim Cuc NguyenDepartment of Cardiovascular sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0009-0003-9426-5324
Daniel L KissDepartment of Cardiovascular Sciences, Center for RNA Therapeutics, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0001-5033-7160
John P CookeDepartment of Cardiovascular sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0003-0033-9138
Anahita MojiriDepartment of Cardiovascular sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0003-0936-5113

Funding

Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
Understanding the mechanisms that regulate cytoplasmic capping and defining itscontributions to post-transcriptional gene regulation (Same as parent grant)R35GM137819 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI KISS, DANIEL LOUIS · 2020 to 2024
$2.3M
Role of S-nitrosylation in TransdifferentiationR01HL133254 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2018 to 2021
$1.6M
Johnson Center for Cellular TherapeuticsNational Heart, Lung and Blood Institute R01HL133254National Heart, Lung and Blood Institute R01HL148338NHLBI NIH HHS R01 HL133254NHLBI NIH HHS R01 HL148338NIGMS NIH HHS R35 GM137819the Cancer Prevention Research Institute of Texas RP200619the National Institute of General Medical Sciences R35GM137819
6 · The paper itself

Abstract

Telomeres shorten with each cell division, acting as a chronometer of cell age. The enzyme telomerase, primarily active in stem cells, reverses telomere erosion. We have previously observed that transient transfection with human TERT mRNA extends telomeres and mitigates hallmarks of senescence in replicatively aged human cells or those affected by Hutchinson-Gilford progeroid syndrome (HGPS). However, due to its short half-life, mRNA requires frequent administration. In this study, we hypothesized that TERT circular (circ) RNA would extend the duration of telomerase expression and be more effective at reversing hallmarks of senescence in endothelial cells derived from HGPS patients. We observe that a single transfection of TERT circRNA is more effective than mRNA in the extension of telomere length, as determined by quantitative fluorescence in situ hybridization. Furthermore, TERT circRNA reduced the number of β-gal positive cells by three-fold and normalized nuclear morphology in HGPS endothelial cells (HGPS-ECs). Moreover, TERT circRNA substantially reduced senescent markers, inflammatory markers, and DNA damage markers, including Progerin, p16, p21, IL-1B, IL-6, IL-8, MCP1, and γH2AX. Additionally, it restored NO production, enhanced cell proliferation, promoted angiogenesis, improved LDL uptake, reduced mitochondrial ROS, and normalized mitochondrial membrane potential more effectively. Our data suggest that TERT circRNA is superior to linear TERT mRNA in reversing processes involved in senescence.

Indexed as

Cellular SenescenceEndothelial CellsProgeriaRNA, CircularTelomeraseHumansRNA, CircularTelomeraseTERT protein, humanagingendothelial cellsRNA therapysenescencetelomerase

Identifiers

PMID39988827
PMCPMC12151875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.